In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...

But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday. VRTX has been the ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted ...